Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation

被引:78
作者
Gao, Yuan [1 ]
Zu, Hui [1 ]
Zhang, Jianjun [1 ]
机构
[1] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Peoples R China
关键词
adefovir dipivoxil; cocrystal; dissolution; saccharin; stability; CRYSTAL; SACCHARIN; PRODRUGS; KINETICS;
D O I
10.1111/j.2042-7158.2010.01246.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives The objectives of this study were to prepare and characterize the novel adefovir dipivoxil-saccharin cocrystal and to demonstrate the enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation. Methods Adefovir dipivoxil-saccharin cocrystal was prepared using a novel solution crystallization approach and scaled up to 30 g for subsequent studies. DSC, IR and XRPD were used to characterize the novel solid form. The stoichiometry of the cocrystal was analysed by HPLC. Dissolution and chemical stability were assessed and compared with marketed adefovir dipivoxil (form 1) used in marketed Hepsera Tablets. Key findings A new solid adefovir dipivoxil-saccharin cocrystal with unique melting point, DSC, FTIR and XRPD data was obtained. The molar ratio of adefovir dipivoxil and saccharin in the cocrystal was determined to be 1 : 1. The cocrystal had a pH-independent dissolution profile and showed a two-fold increase in the dissolution efficiency in water and phosphate buffer (pH 6.8) compared with adefovir dipivoxil. The cocrystal was kinetically much more stable than form 1. Form 1 degraded almost completely at 60 degrees C in 18 days, while adefovir dipivoxil-saccharin cocrystal remained unchanged for 47 days at 60 degrees C. Conclusions This study demonstrated that the dissolution and stability of adefovir dipivoxil could be significantly enhanced by its cocrystal formation with saccharin. The use of cocrystals could be a feasible and valuable approach for improving the physicochemical properties of adefovir dipivoxil.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 25 条
  • [1] Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions
    Andrews, Gavin P.
    Abu-Diak, Osama
    Kusmanto, Febe
    Hornsby, Peter
    Hui, Zhai
    Jones, David S.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (11) : 1580 - 1590
  • [2] [Anonymous], 1997, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms
  • [3] Arimilli M.N., 2002, US Patent, Patent No. [6,451,340, 6451340, 006451340]
  • [4] Indomethacin-saccharin cocrystal:: Design, synthesis and preliminary pharmaceutical characterization
    Basavoju, Srinivas
    Bostrom, Dan
    Velaga, Sitaram P.
    [J]. PHARMACEUTICAL RESEARCH, 2008, 25 (03) : 530 - 541
  • [5] Evaluation of molecular pharmaceutical and in-vivo properties of spray-dried isolated andrographolide-PVP
    Bothiraja, C.
    Shinde, Mukesh B.
    Rajalakshmi, S.
    Pawar, Atmaram P.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (11) : 1465 - 1472
  • [6] 9-{2-[bis(pivaloyloxymethoxy)phosphinylmethoxy]ethyl}adenine dihydrate
    Chang, Ying
    Zheng, Qi-Tai
    Lu, Yang
    [J]. ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2007, 63 : O1014 - O1015
  • [7] *COMM MED PROD HUM, 2009, EUR MED AG SCI DISC
  • [8] Dhumal RS, 2009, J PHARM PHARMACOL, V61, P743, DOI [10.1211/jpp/61.06.0006, 10.1211/jpp.61.06.0006]
  • [9] Crystal engineering of the composition of pharmaceutical phases:: Multiple-component crystalline solids involving carbamazepine
    Fleischman, SG
    Kuduva, SS
    McMahon, JA
    Moulton, B
    Walsh, RDB
    Rodríguez-Hornedo, N
    Zaworotko, MJ
    [J]. CRYSTAL GROWTH & DESIGN, 2003, 3 (06) : 909 - 919
  • [10] Gao YA, 2010, PROG CHEM, V22, P829